We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at ...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Viking Therapeutics ( VKTX – Research Report ), with a price target of $71.00. The company’s shares closed ...

Aisha Al-Muslim is a two-time Pulitzer Prize finalist and development producer for audio at The Wall Street Journal.

Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on scPharmaceuticals (SCPH – Research Report) and ...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was ...

Sarepta Therapeutics Inc. research and ratings by Barron's. View SRPT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

This afternoon we watched Sarepta Therapeutics rise 5.6% to a price of $58.34 per share. The Mid-Cap Pharmaceutical company is now trading -60.85% below its average target price of $149.0. Analysts ...

It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the latest treatment advancements for Duchenne muscular dystrophy.